COVID-19 Treatment Study for High-Risk Adults
A Phase 3 study evaluating an investigational oral antiviral for adults who have recently tested positive for COVID-19 and are at higher risk for severe illness. Contact us immediately after a positive test. Compensation up to $1,100.